Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting - Report - MDSpire

Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting

  • By

  • Tao Shu

  • Xiaobin Shang

  • Yan Zhou

  • July 8, 2026

  • 0 min

Share

Osteoarthritis: Understanding Its Systemic Nature Through Multi-Organ Interactions

Overview

This review highlights the systemic nature of osteoarthritis (OA), emphasizing the role of multi-organ interactions in its pathogenesis.

Background

Osteoarthritis is traditionally viewed as a localized joint disorder, but recent evidence suggests it may also be influenced by systemic factors. The disease affects over 595 million individuals globally, leading to significant economic and health burdens.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Gut microbiota dysbiosis contributes to systemic inflammation and joint homeostasis disruption.
  • Central sensitization in the brain modulates pain perception, influencing OA progression.
  • Liver disorders related to iron and lipid metabolism promote chondrocyte ferroptosis.
  • Renal dysfunction impairs vitamin D metabolism and leads to the accumulation of uremic toxins.

Clinical Implications

Consideration of systemic factors may be important in understanding OA.

Conclusion

This perspective highlights the need for further research into multi-organ interactions in osteoarthritis.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2026) - VA/DOD Clinical Practice Guidelines
  6. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis | MMS/NEJM Continuing Education Center
  7. The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2026) - VA/DOD Clinical Practice Guidelines
  8. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis | MMS/NEJM Continuing Education Center

Original Source(s)

Related Content